SYNTHESIS OF (17-ALPHA,20E/Z)IODOVINYL TESTOSTERONE AND 19-NORTESTOSTERONE DERIVATIVES AS POTENTIAL RADIOLIGANDS FOR ANDROGEN AND PROGESTERONE RECEPTORS

被引:22
作者
ALI, H [1 ]
ROUSSEAU, J [1 ]
VANLIER, JE [1 ]
机构
[1] UNIV SHERBROOKE,FAC MED,MRC,RADIAT SCI GRP,SHERBROOKE J1H 5N4,PQ,CANADA
基金
英国医学研究理事会;
关键词
D O I
10.1016/0960-0760(94)90296-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To develop androgen and progesterone receptor-based radioligands for SPECT imaging we synthesized several radioiodinated 17 alpha-iodovinyl testosterone and 19-nortestosterone analogs and evaluated their biological properties. The synthesis of these compounds proceeds via the (17 alpha,20E/Z)stannyl intermediates and involves addition of tri-n-butyltin hydride to the 17 alpha-ethynyl group of the steroid using either azobisiso butyronitrile or triethylborane as a catalyst. The stannyl derivatives are stereospecifically converted to the corresponding (17 alpha,20E/Z)iodovinyl derivatives using molecular iodine, or to the [I-125]iodovinyl analogs using [I-125]NaI and H2O2. Androgen and progesterone receptor (AR and PgR) binding affinities were measured via a competitive in vitro binding assay. In general 19-nortestosterone derivatives showed higher receptor affinities as compared to the testosterone derivatives. In the latter series the highest PgR binding affinities were observed with the (17 alpha,20Z)iodovinyl-19-nortestosterone (IVNT) (92 vs 100 for R5020) followed by the 7 alpha-methyl analog, whereas the highest AR binding affinity was observed with the 7 alpha-Me-(17 alpha,20Z)IVNT (54 vs 100 for 5 alpha-dihydrotestosterone). These derivatives were also labeled with I-125 and evaluated for their in vivo target organ uptake (prostate and estrogen-primed uterus). The highest PgR-mediated target tissue uptake was observed with the (17 alpha,20Z)-[I-125]IVNT and its 7 alpha-methyl derivatives whereas only one derivative, the 7 alpha-Me-(17 alpha,20Z)-[I-125]IVNT, showed AR-mediated dorsal prostate retention. Although some of the IVNT derivatives have interesting binding properties, the lack of in vivo selectivity does suggest that the I-123-labeled analogs are unlikely to be suitable for imaging of AR and PgR-rich tissues.
引用
收藏
页码:15 / 29
页数:15
相关论文
共 58 条
[1]   SYNTHESIS, RECEPTOR-BINDING, AND TISSUE DISTRIBUTION OF (17-ALPHA,20E)-21-[I-125]IODO-19-NORPREGNA-1,3,5(10),20-TETRAENE-3,17-DIOL AND (17-ALPHA,20Z)-21-[I-125]IODO-19-NORPREGNA-1,3,5(10),20-TETRAENE-3,17-DIOL [J].
ALI, H ;
ROUSSEAU, J ;
GHAFFARI, MA ;
VANLIER, JE .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (10) :1946-1950
[2]   SYNTHESIS, RECEPTOR-BINDING, AND TISSUE DISTRIBUTION OF 7-ALPHA-SUBSTITUTED AND 11-BETA-SUBSTITUTED (17-ALPHA,20E)-21-[I-125]IODO-19-NORPREGNA-1,3,5(10),20-TETRAENE-3,17-DIOLS AND (17-ALPHA,20Z)-21-[I-125]IODO-19-NORPREGNA-1,3,5(10),20-TETRAENE-3,17-DIOLS [J].
ALI, H ;
ROUSSEAU, J ;
GHAFFARI, MA ;
VANLIER, JE .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) :854-860
[3]   SYNTHESIS OF A-RING FLUORINATED DERIVATIVES OF (17-ALPHA,20E/Z)[I-125]IODOVINYLESTRADIOLS - EFFECT ON RECEPTOR-BINDING AND RECEPTOR-MEDIATED TARGET TISSUE UPTAKE [J].
ALI, H ;
ROUSSEAU, J ;
VANLIER, JE .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (21) :3061-3072
[4]  
BARRACK E R, 1987, P155
[5]   STEROID-RECEPTORS, CELLULAR KINETICS, AND LYMPH-NODE STATUS AS PROGNOSTIC FACTORS IN BREAST-CANCER [J].
BENNER, SE ;
CLARK, GM ;
MCGUIRE, WL .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 296 (01) :59-66
[6]  
BRANDES SJ, 1987, MOL PHARMACOL, V32, P391
[7]   7-ALPHA-METHYL-19-NORSTEROIDS - A NEW CLASS OF POTENT ANABOLIC AND ANDROGENIC HORMONES [J].
CAMPBELL, JA ;
LYSTER, SC ;
DUNCAN, GW ;
BABCOCK, JC .
STEROIDS, 1963, 1 (03) :317-324
[8]  
Carlson K E, 1988, Int J Rad Appl Instrum B, V15, P403, DOI 10.1016/0883-2897(88)90010-4
[9]   A COMPARATIVE-STUDY OF THE SELECTIVITY AND EFFICIENCY OF TARGET TISSUE UPTAKE OF 5 TRITIUM-LABELED ANDROGENS IN THE RAT [J].
CARLSON, KE ;
KATZENELLENBOGEN, JA .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 36 (06) :549-561
[10]  
COUNSELL RE, 1981, RADIOPHARMACEUTICALS, P425